History has been created as the world captures the significance of the FDA’s approval of Casgevy (exa-cel), a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, for the treatment...
AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type Asklepios BioPharmaceutical, Inc., a gene therapy firm fully owned and independently operated under Bayer AG, announced the initiation of the Phase I REGENERATE MSA-101 clinical trial ...
Find More
Servier’s Tibsovo (ivosidenib tablets) has received an expanded indication from the FDA, allowing its utilization in patients diagnosed with relapsed or refractory myelodysplastic syndromes that exhibit an IDH1 mutation. This new approval represents the fifth for Tibsovo, which is already recognized for its efficac...
Find More
Niemann-Pick disease type C (NPC) is a rare genetic disorder caused by mutations in cholesterol trafficking proteins. There are two main types, with Type C1 being the most prevalent, accounting for around 95% of cases. While specific epidemiological data on NPC is limited, estimates suggest a prevalence of approxim...
Find More
Molecular modeling, a revolutionary branch of science that seeks to understand and manipulate the intricate world of molecules at the atomic and molecular levels, has seen a remarkable transformation in recent years, owing to the growth in technology. The union of computational science, chemistry, and biology has g...
Find More
Rare diseases affect a larger population than cancer and AIDS combined, with over 7,000 distinct conditions impacting more than 300 million globally. Approximately 1 in 10 individuals are affected by a rare disease, and it often requires several years to receive an accurate diagnosis, averaging around 4.8 years. Ap...
Find More
In recent years, Novo Nordisk has been actively addressing the challenges arising from the launch of its highly popular obesity therapy, Wegovy. However, the pharmaceutical company is now venturing into a less common medical territory with its latest FDA approval. Novo has received FDA approval for Rivfloza, a trea...
Find More
AbbVie Presents Results from Phase III CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma AbbVie has released findings from its Phase III CANOVA trial, which assessed the safety and effectiveness of venetoclax (marketed as VENCLEXTA®/VENCLYXTO®) in combination with dexamethasone ...
Find More
Quick Facts about Netherton Syndrome Netherton syndrome, a less common form of ichthyosis, is a monogenic cutaneous condition characterized by congenital scaly erythroderma, evolving into typical erythematous patches with peripheral scaling, hair shaft abnormalities, and atopic manifestation. Netherton syndr...
Find More
FDA Grants Breakthrough Therapy Designations to Trastuzumab Deruxtecan for HER2+ Solid Tumors, Including mCRC ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been granted two additional Breakthrough Therapy Designations (BTDs) in the United States for the treatment of adult patients with unresectable or metastati...
Find More
Soft Tissue Sarcoma (STS) tumors constitute 1% of all the malignancies. These are rare neoplasms tha.....
Find More
Transthyretin Amyloidosis (ATTR) is a progressive build-up of abnormal deposits of amyloid protein i.....
Find More
Autoimmune hemolytic anemia (AIHA) is a rare acquired autoimmune disease. It is caused by the dysfun.....
Find More
Postoperative Pain is the pain that an individual experiences after a major operation or surgical pr.....
Find More
Molluscum contagiosum is an inflammation of the skin that is caused by the poxvirus Molluscum contag.....
Find More
Diabetic retinopathy is an eye condition that leads to vision loss and blindness in people who have .....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
